News | PET-CT | June 09, 2017

Offers Patient Comfort and Safety

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.


Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion PUREViSION Edition PET/CT system from Toshiba Medical, a Canon Group company. The newest edition of Celesteion allows for ease and efficiency in PET/CT, CT simulation and diagnostic CT exams, to help diagnose and treat oncology patients. The system’s patient-centered design can help deliver a safe and comfortable experience, facilitating better patient compliance.

The Celesteion PUREViSION Edition presents a significant advancement in PET/CT resolution and reconstruction. Offering 70 cm true field-of-view, as well as Toshiba Medical’s SUREFLiGHT reconstruction technology, including Point Spread Function and Time of Flight techniques, the system offers oncologists sharp images and high contrast for improved visualization of small tumors throughout the body. The system’s PUREViSION 16-row CT detector assists in acquiring high-quality CT images, while SEMARTM helps reduce artifacts caused by metal implants, allowing providers to view more clinical information.

Prioritizing patient comfort, the Celesteion PUREViSION Edition features an industry-leading 90 cm wide CT bore that creates a sense of openness to put patients at ease and offers versatile positioning for optimal treatment planning. Ensuring clinicians don’t have to choose between efficiency and safety, the system also comes standard with AIDR 3D iterative dose reduction technology.

“We developed the Celesteion PUREViSION Edition with our customers’ needs in mind,” said Dominic Smith, senior director, CT, PET/CT, and MR Business Units, Toshiba America Medical Systems, Inc. “Accuracy is everything when treating oncology patients and Toshiba Medical is committed to providing our customers with the high-quality imaging solutions they require to provide efficient, effective patient care.”

Toshiba Medical will showcase the Celesteion PUREViSION Edition at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Denver, June 10–14, 2017.

For more information: www.medical.toshiba.com


Related Content

News | PACS

Nov. 30, 2025 — Fujifilm Healthcare Americas Corp. has launched Synapse One, a comprehensive, tailor-made workflow ...

Time December 04, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Information Technology

Dec. 1, 2025 — BioSked has announced a major expansion of its Momentum scheduling platform, introducing one of the first ...

Time December 03, 2025
arrow
News | Ultrasound Imaging

Dec. 1, 2025 — Mindray, a company specializing in patient monitoring, anesthesia, and ultrasound, has unveiled the ...

Time December 02, 2025
arrow
News | Interventional Radiology

Dec. 1, 2025 — GE HealthCare has unveiled the Allia Moveo,1 an image guiding solution designed to enhance mobility and ...

Time December 02, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | Lung Imaging

Dec. 1, 2025 — L&T Technology Services, a provider of AI, Digital & R&D Consulting Services, has announced the ...

Time December 02, 2025
arrow
News | Radiology Imaging

Dec. 1, 2025 — Rad AI has launched next-generation speech recognition technology (patent pending) that dramatically ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
Subscribe Now